These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17569308)

  • 1. [Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Shinagawa H; Izumi T
    Nihon Rinsho; 2007 May; 65 Suppl 5():57-60. PubMed ID: 17569308
    [No Abstract]   [Full Text] [Related]  

  • 2. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 4. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 5. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
    Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 7. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 8. Levosimendan: a new dual-action drug in the treatment of acute heart failure.
    Mebazaa A; Erhardt L
    Int J Clin Pract; 2003 Jun; 57(5):410-6. PubMed ID: 12846347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Digitalis: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Ashizawa N; Yano K
    Nihon Rinsho; 2007 May; 65 Suppl 5():14-8. PubMed ID: 17569306
    [No Abstract]   [Full Text] [Related]  

  • 11. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Schwinger RH; Brixius K
    Dtsch Med Wochenschr; 2005 Apr; 130(15):969-73. PubMed ID: 15812725
    [No Abstract]   [Full Text] [Related]  

  • 14. [Calcium sensitizers--a new group of drugs that increase myocardium contractility].
    Laine M; Lehtonen L; Nieminen MS
    Duodecim; 2000; 116(20):2181-3. PubMed ID: 12017622
    [No Abstract]   [Full Text] [Related]  

  • 15. Levosimendan: calcium sensitizer and inodilator.
    Milligan DJ; Fields AM
    Anesthesiol Clin; 2010 Dec; 28(4):753-60. PubMed ID: 21074750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
    Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs.
    Masutani S; Cheng HJ; Hyttilä-Hopponen M; Levijoki J; Heikkilä A; Vuorela A; Little WC; Cheng CP
    J Pharmacol Exp Ther; 2008 Apr; 325(1):236-47. PubMed ID: 18174383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
    Avgeropoulou C; Andreadou I; Markantonis-Kyroudis S; Demopoulou M; Missovoulos P; Androulakis A; Kallikazaros I
    Eur J Heart Fail; 2005 Aug; 7(5):882-7. PubMed ID: 15921958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.